Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00833443 · ClinicalTrials.gov registry record · Phase 2

Study of Medical Treatment for Methamphetamine Addiction

A Phase 2 study of Substance Abuse and Methamphetamine-dependence, sponsored by University of California, Los Angeles.

Completed
Registry status
Phase 2
Development phase
84
Enrollment target
1
Study location

NCT00833443: Completed Phase 2 study of Substance Abuse and Methamphetamine-dependence, sponsored by University of California, Los Angeles.

NCT00833443 is a Phase 2 study of Substance Abuse and Methamphetamine-dependence that has completed, run by University of California, Los Angeles. The registered enrollment target is 84 participants, below the 5,258-participant average among 58 other Substance Abuse trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00833443, a Phase 2 study of Substance Abuse and Methamphetamine-dependence, has completed, sponsored by University of California, Los Angeles.

COMPLETED
Registry status
Phase 2
Development phase
84 participants
Enrollment target
1
Study location

Study Summary

Currently there are no medications approved for the treatment of methamphetamine addiction. Bupropion is an antidepressant that is approved by the Food and Drug Administration (FDA) for the treatment of depression and for cigarette smoking cessation but is not approved by the FDA for the treatment of methamphetamine addiction. Preliminary research studies suggest that bupropion may help people receiving treatment for methamphetamine addiction to reduce or to stop their methamphetamine use. But results of these studies also suggest that bupropion may help certain groups of patients more than others, such as men versus women and light versus heavy methamphetamine users, although the reasons for this difference are not known. One possibility is that a person's genetic make up may influence whether or not they respond to treatment with bupropion for methamphetamine addiction. The purpose of the study is to determine if bupropion is can help people reduce or stop their methamphetamine use and to investigate whether genetic variations influence whether people respond to treatment with bupropion for methamphetamine addiction, which may help doctors and patients better decide if treatment with bupropion will be beneficial or not. To identify possible genetic variations that influence response to bupropion, we will perform genetic tests on blood or saliva specimens from participants receiving treatment with either bupropion or placebo (which is a pill that contains no medication) in conjunction with standard cognitive behavioral therapy drug counseling. We will compare methamphetamine use, as assessed with urine drug screens, among participants receiving bupropion versus those receiving placebo to determine if bupropion helps people to reduce or stop their methamphetamine use. We will then compare the results of the genetic tests among participants who respond and who do not respond to bupropion. In addition, since the amount of methamphetamine a person uses was associated

Primary Outcome

The mean number of methamphetamine-free urine drug screens provided by participants in each group (range 0-36)

Conditions Studied

Substance Abuse Methamphetamine-dependence Amphetamine Dependence Methamphetamine Pharmacogenetics

Interventions

  • DRUG Bupropion

Study Locations (1)

California

  • UCLA Clinical Research Site 910 Vine St - Los Angeles

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2009-01
Est. Completion 2013-07
Phase Phase 2
University of California, Los Angeles

897 total trials

What the finished NCT00833443 record still lists

NCT00833443 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 5,258-participant average among 58 other Substance Abuse trials with a reported enrollment target (98% lower).

The record links to 5 conditions, with Substance Abuse appearing as the primary indexed condition, and to 1 intervention - of which Bupropion is the first listed.

NCT00833443 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00833443 about?

NCT00833443 is a clinical study titled "Study of Medical Treatment for Methamphetamine Addiction". Currently there are no medications approved for the treatment of methamphetamine addiction. Bupropion is an antidepressant that is approved by the Food and Drug Administration (FDA) for the treatment of depression and for cigarette smoking cessation but is not approved by the FDA for the treatment o...

What is the current status of trial NCT00833443?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2009-01. Estimated completion is 2013-07.

What conditions does trial NCT00833443 study?

This clinical trial studies the following conditions: Substance Abuse, Methamphetamine-dependence, Amphetamine Dependence, Methamphetamine, Pharmacogenetics.

What interventions are being tested in trial NCT00833443?

The interventions under investigation include: Bupropion (DRUG).

Who is sponsoring clinical trial NCT00833443?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00833443 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Substance Abuse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00833443's enrollment target sits among peer trials

84 39th of 58 higher than 19 of 58 other Substance Abuse trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Substance Abuse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02391519 · 84 participants

    Effects of High Altitude on AMPK Activation

  • NCT03838536 · 84 participants · NA

    Synergistic Activity of Human Milk Nutrients and Infant Cognition

  • NCT03884075 · 84 participants · Phase 2

    Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

  • NCT03894917 · 84 participants

    Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00833443, the US trial registry maintained by the National Library of Medicine. NCT00833443 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.